Antibodies that bind IL-4 and/or IL-13 and their uses

Patent metadata

Field	Value
Publication number	US-10759871-B2
Application number	US-201715645765-A
Country	US
Kind code	B2
Filing date	Jul 10, 2017
Priority date	Oct 15, 2007
Publication date	Sep 1, 2020
Grant date	Sep 1, 2020

Abstract

The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

First claim

The invention claimed is:

1. An isolated humanized antibody or antibody fragment thereof that specifically binds IL-4, wherein the antibody or antibody fragment thereof comprises a light chain variable domain comprising CDRs having the amino acid sequences HASQNIDVWLS (SEQ ID NO: 14), KASNLHTG (SEQ ID NO: 15), and QQAHSYPFT (SEQ ID NO: 16) and a heavy chain variable domain comprising CDRs having the amino acid sequences GYSFTSYWIH (SEQ ID NO: 17), IDPSDGETR (SEQ ID NO: 18) and LKEYGNYDSFYFDV (SEQ ID NO: 19).

2. The antibody or antibody fragment thereof of claim 1 , wherein the light chain variable domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:3 and the heavy chain variable domain comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:4.

3. The antibody or antibody fragment thereof of claim 2 , wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO:3 and a heavy chain domain comprises the amino acid sequence of SEQ ID NO:4.

4. The antibody or antibody fragment thereof of claim 1 , wherein the antibody or antibody fragment is an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CH1, CH2 and CH3 domains of a constant region and the light chain comprises a CL domain of a constant region.

5. The antibody or antibody fragment thereof of claim 4 , wherein the antibody is an IgG4 antibody.

6. A pharmaceutical composition comprising the antibody or antibody fragment of claim 1 and a pharmaceutically acceptable carrier.

Assignees

• Sanofi Sa

Inventors

• Rao Ercole
• Mikol Vincent
• Li Danxi
• Kruip Jochen
• Davison Matthew

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• C07K2317/31

  multispecific · CPC title

• A61K47/6845

  the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon · CPC title

• C07K16/247

  IL-4 · CPC title